FGFR2 and cholangiocarcinoma: FDA has approved several targeted therapies for cholangiocarcinoma (CCA), including drugs that target IDH1 mutation and fibroblast growth factor receptor 2 (FGFR2) fusions in genetically selected populations.3, 4